THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTPreferred Stock Purchase Agreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made and entered into as of September 2, 2020, by and among (i) Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), (ii) each holder of Common Stock listed on Schedule A under the heading “Common Stockholders” (the “Existing Common Holders”), (iii) each holder of Series A Preferred Stock listed on Schedule A under the heading “Series A Stockholders” (the “Series A Preferred Holders”), (iv) each holder of Series B Preferred Stock listed on Schedule A under the heading “Series B Stockholders” (the “Series B Preferred Holders”), (v) each holder of Series C Preferred Stock listed on Schedule A under the heading “Series C Stockholders” (together with the Series A Preferred Holders and the Series B Preferred Holders, the “Existing Preferred Holders”), and (vi) each purchaser of Series D Preferred Stock (together with the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred
FINCH THERAPEUTICS, INC. AND MILLENNIUM PHARMACEUTICALS, INC. AMENDED AND RESTATED AGREEMENTAgreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
This Amended and Restated Agreement (“Agreement”) is entered into as of October 21, 2019 (“Restatement Effective Date”) by and between Finch Therapeutics, Inc., a Delaware corporation having its principal office at 200 Inner Belt Road, 4th Floor, Somerville, Massachusetts 02143 (“Finch”), and Millennium Pharmaceuticals, Inc., a Delaware corporation having its principal office at 40 Landsdowne Street, Cambridge, Massachusetts 02139, USA (“Takeda”), an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and sets forth the terms and conditions that will apply to the performance of certain research and development work by each party and the grant by Finch to Takeda of certain licenses to proprietary Finch technology.
ASSET PURCHASE AGREEMENT by and between FINCH THERAPEUTICS, INC., and MICROBIOME HEALTH RESEARCH INSTITUTE, INC. DATED AS OF NOVEMBER 19, 2020Asset Purchase Agreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Delaware
This Asset Purchase Agreement, dated as of November 19, 2020, is made by and between Microbiome Health Research Institute, Inc. d/b/a OpenBiome, a Massachusetts nonprofit corporation (“Seller”) and Finch Therapeutics, Inc., a Delaware corporation (“Purchaser”). Seller and Purchaser are collectively referred to herein as the “Parties” and individually as a “Party.”
UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Arizona
This Exclusive License Agreement (“Agreement”) is made and entered into as of July 3, 2017 (the “Effective Date”) between Arizona Science and Technology Enterprises LLC, an Arizona limited liability company d/b/a Arizona Technology Enterprises (“AzTE”) and Crestovo LLC, a Delaware limited liability corporation (“Company”).
by and between MICROBIOME HEALTH RESEARCH INSTITUTE, INC. and FINCH THERAPEUTICS, INC. November 19, 2020Lmic License Agreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This LMIC License Agreement (the “Agreement”) is entered into as November 19, 2020 (the “Effective Date”), by and between Microbiome Health Research Institute, Inc. d/b/a OpenBiome, a Massachusetts nonprofit corporation, having an address of 2067 Massachusetts Ave, Cambridge, MA 02140 (“OpenBiome”), and Finch Therapeutics, Inc., a corporation organized under the laws of Delaware, having an address of 200 Inner Belt Road, Somerville, MA 02143 (“Finch”). OpenBiome and Finch may each be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO LEASELease • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (“First Amendment”) is made as of January 20, 2017 (“Effective Date”) by and between North River II LLC, a Delaware limited liability company (“Landlord”), with an address of 224 12th Avenue, New York, NY 10001 and NextBiome, Inc., a Delaware corporation, K.N.A. Finch Therapeutics, Inc., a Delaware corporation (“Tenant”).
